SAN FRANCISCO/NEW YORK – Martin Shkreli, chief executive officer of Turing Pharmaceuticals AG, said he would lower the price of the drug Daraprim after being criticized for boosting it fifty-fold to $750 a pill.
“We have agreed to lower the price of Daraprim to a point that is more affordable,” Shkreli said Tuesday in an interview with ABC News. He didn’t say what the new price would be.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.